ATE112165T1 - Verfahren und mittel zur hemmung des proteinveraltens. - Google Patents

Verfahren und mittel zur hemmung des proteinveraltens.

Info

Publication number
ATE112165T1
ATE112165T1 AT86115332T AT86115332T ATE112165T1 AT E112165 T1 ATE112165 T1 AT E112165T1 AT 86115332 T AT86115332 T AT 86115332T AT 86115332 T AT86115332 T AT 86115332T AT E112165 T1 ATE112165 T1 AT E112165T1
Authority
AT
Austria
Prior art keywords
methods
inhibiting
agents
composition
glycosylation
Prior art date
Application number
AT86115332T
Other languages
English (en)
Inventor
Anthony Cerami
Peter Ulrich
Michael Brownlee
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Application granted granted Critical
Publication of ATE112165T1 publication Critical patent/ATE112165T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/43—Guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Birds (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
AT86115332T 1985-11-14 1986-11-05 Verfahren und mittel zur hemmung des proteinveraltens. ATE112165T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/798,032 US4758583A (en) 1984-03-19 1985-11-14 Method and agents for inhibiting protein aging

Publications (1)

Publication Number Publication Date
ATE112165T1 true ATE112165T1 (de) 1994-10-15

Family

ID=25172357

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86115332T ATE112165T1 (de) 1985-11-14 1986-11-05 Verfahren und mittel zur hemmung des proteinveraltens.

Country Status (6)

Country Link
US (1) US4758583A (de)
EP (1) EP0222313B1 (de)
JP (2) JPH0667827B2 (de)
AT (1) ATE112165T1 (de)
DE (1) DE3650080T2 (de)
ES (1) ES2061435T3 (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983604A (en) * 1987-11-13 1991-01-08 The Rockefeller University Inhibitors of nonenzymatic cross-linking
US5137916A (en) * 1985-11-14 1992-08-11 The Rockefeller University Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
US4978684A (en) * 1987-11-13 1990-12-18 The Rockefeller University Method and agents for preventing staining of teeth
US5801200A (en) * 1984-03-19 1998-09-01 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5128122A (en) * 1984-03-19 1992-07-07 The Rockefeller University Method and agents for preventing staining of teeth
US5869534A (en) * 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US5399560A (en) * 1984-03-19 1995-03-21 The Rockefeller University 1,2,4-triazine products resulting from the inhibition of advanced glycosylation
US5468777A (en) * 1984-03-19 1995-11-21 The Rockefeller University Method and agents for preventing and reversing the staining of teeth
US5534540A (en) * 1984-03-19 1996-07-09 Alteon Inc. Methods of inhibiting the advanced glycosylation of proteins using tetramic and tetronic acids and compositions therefor
US4900747A (en) * 1984-03-19 1990-02-13 The Rockefeller University Method and agents for removing advanced glycosylation endproducts
US5262152A (en) * 1984-03-19 1993-11-16 The Rockefeller University Amidrazones and derivatives thereof
US5334617A (en) * 1984-03-19 1994-08-02 The Rockefeller University Amino acids useful as inhibitors of the advanced glycosylation of proteins
US5811075A (en) * 1984-03-19 1998-09-22 The Rockefeller University Method and agents for removing advanced glycosylation endproducts
US5700447A (en) * 1992-05-21 1997-12-23 The Picowder Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5852009A (en) * 1984-03-19 1998-12-22 The Rockefeller University Compositions, including pharmaceutical compositions, for inhibiting the advanced glycosylation of proteins, and therapeutic methods based thereon
US5140048A (en) * 1984-03-19 1992-08-18 The Rockefeller University Inhibitors of nonenzymatic cross-linking
US5114943A (en) * 1984-03-19 1992-05-19 The Rockefeller University Amino-substituted pyrimidines, derivatives and methods of use therefor
USRE35465E (en) * 1984-03-19 1997-02-25 The Rockefeller University Method and agents for removing advanced glycosylation endproducts
US4665192A (en) * 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole
US5733524A (en) * 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5733933A (en) * 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5514676A (en) * 1984-03-19 1996-05-07 The Rockefeller University Amino-benzoic acids and derivatives, and methods of use
US5612332A (en) * 1984-03-19 1997-03-18 Alteon Inc. Di- and triaminoguanidines, and methods of use
US5218001A (en) * 1984-03-19 1993-06-08 The Rockefeller University Inhibitors of the advanced glycosylation of proteins and methods of use therefor
US5356895A (en) * 1984-03-19 1994-10-18 The Rockefeller University 1,4 piperizino inhibitors of non-enzymatic cross-linking of proteins
US5476849A (en) * 1984-03-19 1995-12-19 The Rockefeller University Methods for glycosylation inhibition using amino-benzoic acids and derivatives
US5254593A (en) * 1984-03-19 1993-10-19 The Rockefeller University Compositions containing biguanides and derivatives thereof as inhibitors of nonenzymatic cross-linking
US5126442A (en) * 1987-09-17 1992-06-30 The Rockefeller University Advanced glycosylation endproducts and associated methods
US5017696A (en) * 1987-09-17 1991-05-21 The Rockefeller University Advanced glycosylation end products and associated methods
EP0323590A3 (de) * 1987-12-24 1990-05-02 Ono Pharmaceutical Co., Ltd. Carbazoyl-Derivate
EP0325936A3 (de) * 1988-01-16 1990-01-17 Ono Pharmaceutical Co., Ltd. Aminoguanidin-Derivate und für die Maillardreaktion inhibitorische Substanzen, die sie als aktive Inhaltsstoffe enthalten
CA1332572C (en) * 1988-01-29 1994-10-18 Anthony Cerami Method and agents for preventing staining of teeth
EP0339496A3 (de) * 1988-04-26 1991-05-08 Ono Pharmaceutical Co., Ltd. Aminoguanidine Derivate
JP2817219B2 (ja) * 1988-09-08 1998-10-30 武田薬品工業株式会社 カルバジン酸誘導体、その製造法及び製剤
AT393079B (de) * 1989-03-06 1991-08-12 Lubec Gert Pharmazeutische verwendung von agmatin
US5077313A (en) * 1988-11-25 1991-12-31 Gert Lubec Process for inhibiting pathological collagen cross-linking in diabetes patients
AT393080B (de) * 1988-11-25 1991-08-12 Lubec Gert Pharmazeutische verwendung von arginin (salzen)
ATE83658T1 (de) * 1988-11-25 1993-01-15 Lubec Gert Behandlung von durch glucose ausgeloester quervernetzung von collagen bei diabetes mellitus-patienten durch arginin, spermidin, kreatin oder agmatin.
US5132230A (en) * 1989-03-28 1992-07-21 Isolab, Inc. Primary standard and method of making secondary standards for calibration of glycated protein assays
US5108930A (en) * 1990-02-20 1992-04-28 Alteon Inc. Aminoguanidine assay and applications thereof
TW221689B (de) * 1991-08-27 1994-03-11 Otsuka Pharma Co Ltd
US5837738A (en) * 1991-12-16 1998-11-17 Washington University Method of inhibiting nitric oxide formation
US5246971A (en) * 1991-12-16 1993-09-21 Washington University Method of inhibiting nitric oxide formation
ATE191847T1 (de) * 1991-12-16 2000-05-15 Univ Washington Verwendung von aminoguamidin zur herstellung eines arzneimittels zur unterdrückung der stickoxidbildung
US5358969A (en) * 1991-12-16 1994-10-25 Washington University Method of inhibiting nitric oxide formation
US5246970A (en) * 1991-12-16 1993-09-21 Washington University Method of inhibiting nitric oxide formation
US5710181A (en) * 1991-12-16 1998-01-20 Washington University Inhibition of nitric oxide formation in inflammatory bowel disease
DK0636023T3 (da) * 1992-04-15 1999-12-06 Alteon Inc Fremgangsmåde til spraytørring af aminoguanidin
DE4222980A1 (de) * 1992-07-13 1994-01-20 Cassella Ag Verwendung von 2-(N-(2-Aminoethyl)amino)-essigsäure-derivaten
EP0679088B1 (de) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonale abgabe von aktiven fragmenten des parathormons
US5453514A (en) * 1992-12-25 1995-09-26 Yamanouchi Pharmaceutical Co., Ltd. Pyrazole derivatives and compositions and methods of use as maillard reaction inhibitors
US5500439A (en) * 1993-12-09 1996-03-19 Alteon Inc. Aminopyrazoles
US6410598B1 (en) 1994-02-03 2002-06-25 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
AU692237B2 (en) * 1994-02-03 1998-06-04 Picower Institute For Medical Research, The Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
ATE416755T1 (de) 1994-03-07 2008-12-15 Nektar Therapeutics Verfahren und zusammensetzung für die pulmonale darreichung von insulin
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
JP3333309B2 (ja) * 1994-04-08 2002-10-15 鐘淵化学工業株式会社 ケトアミン含有タンパク質吸着体
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
WO1996012483A1 (en) * 1994-10-25 1996-05-02 Washington University Method of inhibiting nitric oxide formation
PT793646E (pt) * 1994-11-23 2002-03-28 Biovitrum Ab Carboxilatos de aminoguanidina destinados ao tratamento de diabetes mellitus nao-insulinodependente
US5994577A (en) * 1994-11-23 1999-11-30 Larsen; Scott D. Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus
US5661139A (en) * 1995-01-13 1997-08-26 Alteon Inc. Bis-(2-aryl) hydrazones
US5698563A (en) * 1995-01-13 1997-12-16 Alteon Inc. Bis- hydrazones!
FI119756B (fi) * 1995-01-18 2009-03-13 Alteon Inc Tiatsoliumyhdisteiden käyttö pitkälle edenneen glykosylaation lopputuotteiden muodostumisen estossa ja suunnan muutoksessa
DE69629176T2 (de) * 1995-01-18 2004-06-03 Alteon Inc. Verwendung von thiazoliumverbindungen zum verhindern und umkehren der bildung von endprodukten der fortgeschrittenen glykosylierung
US5656261A (en) * 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
JP3542665B2 (ja) * 1995-07-07 2004-07-14 株式会社資生堂 抗老化皮膚外用剤、コラーゲン架橋阻害皮膚外用剤及び抗紫外線皮膚外用剤
US6228858B1 (en) 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US6750209B1 (en) * 1995-09-12 2004-06-15 Kansas University Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US6436969B1 (en) * 1995-09-12 2002-08-20 Kansas University Medical Center Research Institute Inc. Dialysis solutions and methods
US5850840A (en) * 1995-11-15 1998-12-22 Alteon Inc. Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
US5877217A (en) * 1995-12-26 1999-03-02 Alteon Inc. N-acylaminoalkyl-hydrazinecarboximidamides
NZ326238A (en) * 1995-12-26 1999-11-29 Alteon Inc Compositons and methods for inhibiting nonenzymatic cross-linking and glycosylation (protein aging) using N-acylaminoalkylhydrazine carboximidamides
US6110968A (en) * 1995-12-26 2000-08-29 The Picower Institute For Medical Research Methods for treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
US5869527A (en) * 1995-12-29 1999-02-09 Alteon Inc. 6-(N-carboxymethylamino)caproate, salts thereof and methods of use therefor
US5932578A (en) * 1996-03-28 1999-08-03 Alteon Inc. Triazine compounds and methods of use therefor
US5939069A (en) * 1996-08-23 1999-08-17 University Of Florida Materials and methods for detection and treatment of immune system dysfunctions
US20030013746A1 (en) * 1996-09-10 2003-01-16 University Of Kansas Medical Center. Advanced glycation end-product intermediaries and post-amadori inhibition
US6372269B1 (en) * 1997-09-09 2002-04-16 Cerveceria Polar, C.A. Compositions for producing fermented malt beverages
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
CN1150034C (zh) 1998-08-24 2004-05-19 黑川清 羰基压力改善剂和腹膜透析液
CA2343357A1 (en) * 1998-09-25 2000-04-06 Glycox Corporation Limited Fructosamine oxidase assay: methods and materials
EP1115389B1 (de) 1998-09-25 2014-03-12 PhilERA New Zealand Limited Antagonisten und agonisten der fructosamin oxidase
PT1143954E (pt) 1998-12-01 2004-12-31 Univ Kentucky Res Found Utilizacao de derivados de acido nocotinico para o tratamento de danos no adn em celulas da pele
EP1219302A4 (de) * 1999-05-12 2005-04-27 Kurokawa Kiyoshi Fangender wirkstoff für blut carbonyl-verbindungen
RU2215000C2 (ru) 1999-10-06 2003-10-27 Торрент Фармасьютикалз Лтд. Производные солей пиридиния, способ их получения, фармацевтические композиции на их основе и способы лечения
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
ATE312354T1 (de) * 2000-05-23 2005-12-15 Univ Southern California Diagnose von alzheimerkrankheit unter verwendung von ldl-rezeptor-protein-1
US6521645B2 (en) 2000-11-20 2003-02-18 The University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
CN1259316C (zh) 2001-04-05 2006-06-14 托伦脱药品有限公司 用于老龄相关性和糖尿病性血管系统并发症的杂环类化合物
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
CN1649577A (zh) * 2002-03-08 2005-08-03 普罗特米克斯公司 预防和/或治疗心血管疾病和/或相关的心衰
US6781039B2 (en) * 2002-05-07 2004-08-24 Stine Seed Farm, Inc. Soybean cultivar S010360
CA2875522A1 (en) 2002-08-20 2004-03-04 Philera New Zealand Limited Dosage forms and related therapies
JP2006174845A (ja) * 2003-04-04 2006-07-06 House Foods Corp 食品中のアクリルアミドの低減方法
US20050014747A1 (en) * 2003-04-18 2005-01-20 Emily Reinhard Dihydrothiazine prodrugs of thiazolium agents
US7608586B2 (en) * 2003-06-11 2009-10-27 The University Of Rochester Soluble low-density lipoprotein receptor related protein binds directly to Alzheimer's amyloid-beta peptide
EP1694317A4 (de) * 2003-12-19 2010-05-12 Protemix Corp Ltd Kupfer-antagonisten-verbindungen
PT1778618E (pt) 2004-07-19 2014-03-04 Philera New Zealand Ltd Síntese de trietilenotetraminas
FR2883873B1 (fr) 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
US9005643B2 (en) * 2008-04-04 2015-04-14 North Carolina State University Inhibition of bacterial biofilms with imidazole-phenyl derivatives
CN102459175A (zh) 2009-05-07 2012-05-16 托蓝特医药公司 用于治疗糖尿病的哌啶衍生物
US9221765B2 (en) 2009-06-10 2015-12-29 North Carolina State University Inhibition and dispersion of bacterial biofilms with benzimidazole derivatives
IT1403257B1 (it) * 2010-12-06 2013-10-17 Intercos Italiana Composizioni cosmetiche contenenti composti con azione anti-glicazione, da usare per prevenire e rallentare il processo di invecchiamento cutaneo
EP2664606B1 (de) 2012-04-25 2016-09-14 Ueno Fine Chemicals Industry, Ltd. Hemmer der Produktion von fortgeschrittenen Glykierungsendprodukten
RU2634594C1 (ru) * 2016-11-30 2017-11-01 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Ингибиторы образования конечных продуктов гликирования на основе азопроизводных фенилсульфокислот
US20230210871A1 (en) 2017-10-12 2023-07-06 The Limited Company Research And Development Company "Medbiopharm" Use of sulfasalazine as an inhibitor of the formation of advanced glycation end products
KR102022338B1 (ko) * 2018-08-06 2019-09-18 이건무 당과 아미노산을 함유하는 안정한 수액제 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54138136A (en) * 1978-04-20 1979-10-26 Takio Izawa Decomposition preventing method by using amino acid type compound
US4629692A (en) * 1982-12-06 1986-12-16 Miles Laboratories, Inc. Immunoassay for nonenzymatically glucosylated proteins and protein fragments an index of glycemia
JPS6027371A (ja) * 1983-07-27 1985-02-12 Sanraku Inc 食品防腐剤
JPS60118174A (ja) * 1983-11-28 1985-06-25 Kazuji Fukunaga 変質防止法
US4665192A (en) * 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole

Also Published As

Publication number Publication date
EP0222313B1 (de) 1994-09-28
US4758583A (en) 1988-07-19
ES2061435T3 (es) 1994-12-16
JPH03103163A (ja) 1991-04-30
EP0222313A3 (en) 1990-02-28
DE3650080D1 (de) 1994-11-03
JPH0667827B2 (ja) 1994-08-31
EP0222313A2 (de) 1987-05-20
DE3650080T2 (de) 1995-02-16
AU6495886A (en) 1987-05-21
AU610056B2 (en) 1991-05-16
JPS62142114A (ja) 1987-06-25

Similar Documents

Publication Publication Date Title
ATE112165T1 (de) Verfahren und mittel zur hemmung des proteinveraltens.
WO1993014750A3 (en) Amino acids useful as inhibitors of the advanced glycosylation of proteins
EP0316852A3 (de) Hemmer von nichtenzymatischer Quervernetzung
NO982976D0 (no) N-acylaminoalkylhydrazinkarboksimidamider
DE69629176D1 (de) Verwendung von thiazoliumverbindungen zum verhindern und umkehren der bildung von endprodukten der fortgeschrittenen glykosylierung
DE69532996D1 (de) Peptidanaloge des menschlichen basischen myelinproteins
EA199700294A1 (ru) Фармацевтическая композиция, содержащая ингибиторы протонного насоса
DE69931793D1 (de) Verfahren für die behandlung der multiplen sklerose mittels peptidanalogen des menschlichen basischen myelinproteins
DE69630007D1 (de) Futtermittelzusatzzusammensetzung für Wiederkäuer, enthaltend Komplexsalze von Phosphorsäure, Aminosäure und mehrwertigem Metall
EP0327919A3 (de) Verfahren und Mittel zur Verhinderung der Färbung der Zähne
EP0657520B1 (de) Antioxidans
AU6115494A (en) Adipocyte differentiation inhibitor peptide and adipocyte differentiation inhibitor containing said peptide as active ingredient
PT83705A (en) Various n-substituted 3-piperidine carboxylic acids or n-substituted 3-pyridinecarboxylic acids and derivatives thereof
DE69113862D1 (de) Verfahren zum Stabilisieren des Geschmacksveränderungsmittels.
WO1996021450A3 (en) Bis-[hydrazones]
JPH05320067A (ja) 抗菌剤とこの抗菌剤を用いて物品を処理する方法
MX9803898A (es) Metodo y mejorado y agentes para inhibir el envejecimiento de proteina.
HUT52117A (en) Process for producing amblyommin and process for producing pharmaceutical compositions comprising such compound as active ingredient
ATE223384T1 (de) Substituierte imidazoliunsalze und deren verwendung zur hemmung der proteinalterung
ATE231845T1 (de) 1,2,4-triazinderivate zur inhibierung der proteinglycosylierung
Ulrich et al. 1, 4 piperizino inhibitors of non-enzymatic cross-linking of proteins
EP0401004A3 (de) Zusammensetzung zur Verwendung bei der Behandlung von Fischmaterial während der Herstellung eines Fischprodukts, Herstellungsmethode eines derartigen Fischprodukts und verbessertes Fischprodukt
DE69714639D1 (de) Mischungen aus Gluten und Laktose
FI974601A0 (fi) Veren triglyseriditason kohoamista estävä peptidi ja mainittua peptidiä aktiivisena aineosana sisältävä veren triglyseriditason kohoamisen estäjä
ES8800686A1 (es) Un procedimiento para la preparacion de derivados aminoacidicos de l-fosfoserina.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee